HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.

AbstractBACKGROUND AND OBJECTIVE:
Several studies have suggested that thrombin-activatable fibrinolysis inhibitor (TAFI) levels are associated with the risk of arterial thrombosis, but results have been contradictory. We studied functional TAFI levels and TAFI gene polymorphisms in 124 patients with a recent ischemic stroke and 125 age- and sex-matched controls to establish the role of TAFI in ischemic stroke.
METHODS AND RESULTS:
Functional TAFI levels, defined as TAFI-related retardation (RT), the difference in clot lysis time (LT) in the absence or presence of a specific activated TAFI inhibitor (potato carboxypeptidase inhibitor [PCI]), were higher in patients than controls (19.5 +/- 4.2 vs. 17.7 +/- 3.7 min, P < 0.005). Clot LTs in the presence of PCI, which were independent of TAFI, were also increased in ischemic stroke patients. This indicates that in these patients fibrinolysis is impaired not only by high TAFI levels, but also by other mechanisms. Individuals with functional TAFI levels in the highest quartile had an increased risk of ischemic stroke compared with the lowest quartile [odds ratio (OR) 4.0, 95% confidence interval (CI): 1.6-9.8]. In an unselected group of 36 of the 125 stroke patients functional TAFI levels were also measured at 3 months, and were persistently high. This indicates that increased functional TAFI levels after stroke are not caused by an acute phase reaction. No difference was found between patients and controls with respect to TAFI genotype distribution.
CONCLUSIONS:
Increased functional TAFI levels, resulting in decreased fibrinolysis, are associated with an increased risk of ischemic stroke.
AuthorsF W G Leebeek, M P J Goor, A H C Guimaraes, G-J Brouwers, M P M Maat, D W J Dippel, D C Rijken
JournalJournal of thrombosis and haemostasis : JTH (J Thromb Haemost) Vol. 3 Issue 10 Pg. 2211-8 (Oct 2005) ISSN: 1538-7933 [Print] England
PMID16092924 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Carboxypeptidase B2
Topics
  • Adult
  • Aged
  • Brain Ischemia (epidemiology, etiology)
  • Carboxypeptidase B2 (blood, genetics, physiology)
  • Case-Control Studies
  • Europe
  • Female
  • Fibrinolysis
  • Genotype
  • Humans
  • Kinetics
  • Male
  • Middle Aged
  • Molecular Epidemiology
  • Polymorphism, Genetic
  • Prospective Studies
  • Risk
  • Stroke (epidemiology, etiology)
  • White People

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: